Novo Nordisk
OEM : Pharmaceutical
For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.
Assembly Line
Bactolife Raises EUR 30 million in Series A Financing
Bactolife A/S (“Bactolife”), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that it has successfully raised EUR >30 million since its April 2021 seed round.
The financing round is led by ATHOS with participation from the Bill & Melinda Gates Foundation and existing investors, incl. Novo Holdings. Proceeds from the financing will enable Bactolife to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities. By doing so, the company aims at retaining its first mover advantage to transform human and animal health with target specific Binding Proteins™.
MiR500 at Novo Nordisk
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities.
Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s R&D.
HoloLens 2 helps Novo Nordisk employees see work in new ways
The pharmaceutical giant, a leader in the global production of diabetes medicine, has been pioneering the use of emerging digital technologies for everything from simplifying floor operations in their manufacturing facilities across the globe to conducting virtual site visits from thousands of miles away. Some of those solutions include Microsoft HoloLens 2, Microsoft Dynamics 365 Remote Assist, Microsoft Dynamics 365 Guides and Microsoft Power Platform. This includes introducing what is known as augmented instructions, via HoloLens 2, to shop floor employees, providing them with new possibilities to support both process performance and getting onboarded for new procedures.